X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6648) 6648
Publication (948) 948
Book Review (49) 49
Book Chapter (38) 38
Dissertation (15) 15
Conference Proceeding (9) 9
Magazine Article (3) 3
Book / eBook (2) 2
Newspaper Article (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4666) 4666
humans (4604) 4604
cancer (2733) 2733
p53 (2630) 2630
oncology (2419) 2419
female (1988) 1988
animals (1870) 1870
mutation (1851) 1851
p53 protein (1695) 1695
gene expression (1672) 1672
tumor suppressor protein p53 - genetics (1644) 1644
tumor suppressor protein p53 - metabolism (1559) 1559
apoptosis (1539) 1539
tumors (1536) 1536
cell biology (1531) 1531
tumor proteins (1508) 1508
expression (1378) 1378
genetic aspects (1361) 1361
male (1293) 1293
mice (1263) 1263
research (1109) 1109
proteins (1044) 1044
biochemistry & molecular biology (1029) 1029
middle aged (1029) 1029
analysis (1015) 1015
cell line, tumor (999) 999
genes (975) 975
article (922) 922
prognosis (914) 914
aged (871) 871
cell cycle (869) 869
gene expression regulation, neoplastic (851) 851
multidisciplinary sciences (819) 819
adult (782) 782
research article (770) 770
signal transduction (763) 763
breast cancer (740) 740
medicine (716) 716
health aspects (694) 694
deoxyribonucleic acid--dna (682) 682
genetics & heredity (662) 662
gene expression profiling (646) 646
metastasis (640) 640
genomes (611) 611
gene-expression (609) 609
pathology (609) 609
biology (601) 601
cell proliferation (595) 595
development and progression (595) 595
dna damage (586) 586
science (572) 572
genomics (558) 558
survival (548) 548
kinases (543) 543
immunohistochemistry (532) 532
gene (527) 527
cells (522) 522
chemotherapy (511) 511
dna (507) 507
genetics (504) 504
carcinoma (501) 501
care and treatment (496) 496
mutations (496) 496
activation (482) 482
breast-cancer (468) 468
physiological aspects (456) 456
stem cells (450) 450
tumorigenesis (429) 429
medical prognosis (424) 424
studies (413) 413
transcription (412) 412
aged, 80 and over (406) 406
biomarkers (406) 406
dna methylation (403) 403
protein (401) 401
micrornas - genetics (398) 398
tumor suppressor genes (393) 393
microrna (392) 392
cancer therapies (384) 384
medical research (383) 383
dna-damage (382) 382
genes, p53 (374) 374
risk factors (364) 364
patients (361) 361
growth (355) 355
breast neoplasms - genetics (350) 350
micrornas (348) 348
neoplasms - genetics (342) 342
carcinogenesis (339) 339
phosphorylation (338) 338
dna repair (333) 333
identification (327) 327
in-vivo (324) 324
medicine, research & experimental (320) 320
down-regulation (317) 317
genetic research (314) 314
transcription factors (312) 312
rna (309) 309
gene mutations (307) 307
molecular biology (304) 304
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6659) 6659
French (15) 15
German (7) 7
Chinese (3) 3
Russian (2) 2
Croatian (1) 1
Italian (1) 1
Korean (1) 1
Latvian (1) 1
Polish (1) 1
Portuguese (1) 1
Spanish (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 4/2012, Volume 109, Issue 15, pp. 5832 - 5837
Human Epidermal Growth Factor Receptor 2-positive (HER2⁺) breast cancer (BC) is a highly aggressive disease commonly treated with chemotherapy and anti-HER2... 
Chemotherapy | Health outcomes | Disease models | Stem cells | Breast cancer | Signatures | Cells | Cell transplantation | Tumors | Cancer | Prognostic signature | breast cancer | Cancer stem cells | HER2 | Mouse models | mouse models | STEM-CELLS | SUBTYPES | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | HER2(+) breast cancer | cancer stem cells | IDENTIFICATION | TUMORIGENESIS | prognostic signature | P53 | Prognosis | Neoplastic Stem Cells - drug effects | CD24 Antigen - metabolism | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Agents - therapeutic use | Gene Expression Profiling | Intercellular Signaling Peptides and Proteins - metabolism | Neoplastic Stem Cells - metabolism | Serrate-Jagged Proteins | Antibodies, Monoclonal, Humanized - pharmacology | Neoplastic Stem Cells - pathology | Estrogen Receptor alpha - metabolism | Female | Neoadjuvant Therapy | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Gene Expression Regulation, Neoplastic - drug effects | Genes, Neoplasm - genetics | Jagged-1 Protein | Calcium-Binding Proteins - metabolism | Antibodies, Monoclonal, Humanized - therapeutic use | Treatment Outcome | Breast Neoplasms - drug therapy | Cell Division - drug effects | Animals | Breast Neoplasms - genetics | Signal Transduction - drug effects | Cell Differentiation - drug effects | Mice | Trastuzumab | Biological Sciences | HER2+ breast cancer
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 03/2013, Volume 27, Issue 3, pp. 595 - 603
Journal Article
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 09/2011, Volume 129, Issue 6, pp. 1532 - 1536
Journal Article
European Urology, ISSN 0302-2838, 2015, Volume 69, Issue 5, pp. 855 - 862
Abstract Background Gene expression profiling (GEP) suggests there are three subtypes of muscle-invasive urothelial cancer (UC): basal, which has the worst... 
Urology | Basal | Urothelial cancer | Dose-dense methotrexate cisplatin | Gene expression profiling | Luminal | Neoadjuvant | Subtype | Bevacizumab | p53 | METASTASIS | SUBTYPES | TUMORS | UROLOGY & NEPHROLOGY | CYSTECTOMY | CARCINOMA | INVASIVE BLADDER-CANCER | Urinary Bladder Neoplasms - classification | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Middle Aged | Carcinoma, Transitional Cell - secondary | Transcriptome | Bone Neoplasms - secondary | Male | Gene Expression Profiling | Vinblastine - administration & dosage | Tumor Suppressor Protein p53 - genetics | Cisplatin - administration & dosage | Urinary Bladder Neoplasms - genetics | Urinary Bladder Neoplasms - pathology | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Carcinoma, Transitional Cell - genetics | Doxorubicin - administration & dosage | Bevacizumab - administration & dosage | Proportional Hazards Models | Survival Rate | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Carcinoma, Transitional Cell - classification | Cystectomy | Carcinoma, Transitional Cell - drug therapy | Methotrexate - administration & dosage | Aged | Neoplasm Staging | Antimitotic agents | Anthracyclines | Patient outcomes | Adjuvant treatment | Product development | Genetic aspects | Tumor proteins | Antineoplastic agents | Gene expression | Cancer | Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin
Journal Article
Journal Article